Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Ventricular Flutter”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 757 records · Page 42Linked to original sources
PubMed1981

[The transesophageal approach to the heart in electrotherapy of trachycardiac arrhythmias. I. Transesophageal electrostimulation procedure].

Transoesophageal electrostimulation techniques were used in 124 cases of different tachycardiac disturbances of rhythm. By means of highly frequent transoesophageal atrial stimulation we succeeded in transformating into sinus rhythm in 46% of the patients with atrial flutter, in 29% of the cases with atrial tachycardias and in 75% of the patients with av-junctional tachycardias. At least atrial fibrillation (with decrease of the ventricular frequency) could be induced in 48% in pre-existing auricular flutter, in 38% in auricular tachycardias and in 15% in av-junctional atrial (partial success of therapy). Sinus tachycardias, atrial fibrillation and ventricular tachycardias could practically not be influenced by highly frequent transoesophageal atrial stimulation. Moreover, for the first time the techniques of the doubled or coupled atrial stimulation, in 2 cases also ventricular stimulations with higher frequency were tested on transoesophageal way and were introduced into the treatment of tachycardiac disturbances of rhythm. The therapeutic results of transoesophageal electrostimulation techniques seem to be comparable entirely with those of intracardiac stimulations, in which cases the non-invasive and uncomplicated techniques are accessible also to institutions without possibilities of heart catheterization.

Adult↗
PubMed2002

[Atrial flutter in neonates and infants: diagnosis and treatment].

Between 1995 and 2002, 5 patients with a mean age of 32 years have been treated for atrial flutter in the Department of Paediatric Cardiology at Hospital La Rabta. In all cases, diagnosis was established on surface electrocardiogram (12 leads. All patients had a normal heart. The 3 infants were in heart failure and In the 2 neonates, the arrhythmia was well tolerated despite a very fast ventricular rate. Reduction of the first episode of atrial flutter was possible by cardioversion in 3 patients, 2 of them had a good impregnation with Amiodarone. The two neonates died at 8th and 10th day of life. In the long term follow-up, on infant presented two recurrent episodes at 4 months x 2 years. Atrial flutter, when diagnosed in neonatal period is a rare but serious rhythm disturbance. The mechanism of activation of this rhythm disturbance remains unknown in the foetus, neonate and infant.

Amiodarone↗
PubMed1987

Intravenous flecainide acetate for the clinical management of paroxysmal tachycardias.

Intravenous flecainide acetate (2 mg/kg) was administered to 40 patients undergoing routine electrophysiological evaluation for the investigation of recurrent paroxysmal tachycardias. Ten patients had recurrent atrial flutter, 11 patients had recurrent atrial fibrillation, one of whom also had paroxysmal left atrial tachycardia, and 19 patients had recurrent ventricular tachyarrhythmias (17 with recurrent ventricular tachycardia and 2 with recurrent fascicular tachycardia). Flecainide was administered during tachycardia (over 5 to 10 minutes) to all patients with atrial flutter, to 10 patients with atrial fibrillation, and to 17 patients with ventricular tachyarrhythmias. In the remaining 3 patients with ill-sustained arrhythmias flecainide was administered during sinus rhythm and reinitiation of tachycardia was then attempted. Flecainide restored sinus rhythm in only 2 patients with atrial flutter (20%), in 9 patients with atrial fibrillation (90%), in 12 patients with ventricular tachycardia (80%), and in one of the 2 patients with fasicular tachycardia. Flecainide also successfully terminated the left atrial tachycardia. Two patients experienced proarrhythmic side effects during flecainide administration, one of whom required intervention by cardioversion. Minor dose effects included oral paresthesia, transient drowsiness or dizziness, and occasional visual blurring. Flecainide acetate is an effective antiarrhythmic agent for the acute termination of recent onset paroxysmal atrial and ventricular tachyarrhythmias.

Adolescent↗
PubMed1984

[Endocardial cardioversion--a new method for treating recurrent ventricular tachycardia].

The effect of endocardial cardioversion was investigated in 17 patients (aged 26-76 years), ten of them with ventricular tachycardia, either spontaneous or initiated by programmable stimulation. During a total of 14 days of observation there were 33 episodes of spontaneous or induced ventricular tachycardia. A special cardioverter catheter had been placed into the right ventricle and endocardial microshocks were given ranging from 0.05-2.0 J. All patients could feel the shock, but in most instances it was mild to moderate, in only one painful. The tachycardia was slowed in 20% of all microshocks, moderate acceleration occurred in 6%, while in 71% the tachycardia rate remained unchanged. In 7 out of 65 microshocks sinus rhythm occurred spontaneously, after an interval in which the tachycardia slowed. Atrial fibrillation was induced in 6% of cases, but there was no instance of ventricular fibrillation. Reversion directly to sinus rhythm after endocardial cardioversion occurred in 26 of 33 episodes of ventricular tachycardia, while in 7 episodes the tachycardia rate slowed. In no case was it necessary to use external DC cardioversion to terminate a ventricular tachycardia. Threshold values for successful cardioversion of ventricular tachycardia averaged 0.77 (+/- 0.63) J. In one patient, atrial flutter with a relatively high A-V conduction rate was converted into atrial fibrillation by an intra-atrial microshock of 5.0 J. Thus endocardial cardioversion proved effective and safe in terminating ventricular tachycardia, even in patients in whom anti-tachycardic ventricular pacemaker stimulation had failed. The method is apparently not suitable for the conversion of supraventricular tachy-arrhythmias to sinus rhythm.

Adult↗
PubMed2001

Conversion of atrial fibrillation by the experimental antiarrhythmic drug tedisamil in two canine models.

INTRODUCTION: Tedisamil is an experimental bradycardic agent possessing action potential-prolonging effects. It has been proven effective in terminating ventricular arrhythmias in several animal models and atrial flutter in a conscious dog model. There are no reports to date evaluating tedisamil's efficacy in terminating atrial fibrillation (AF). METHODS AND RESULTS: Two different canine models of AF were used. One group of dogs (n = 6) was subjected to 28 days of chronic fibrillatory pacing at 50 Hz using an implantable neural stimulator. Sustained AF was achieved in all dogs within 14 days of initiating pacing. A second set of dogs (n = 5) had AF induced via bilateral vagal stimulation. Tedisamil 1 mg/kg was 100% effective in terminating AF in both models. Cardioversion was associated with a statistically significant prolongation of the fibrillatory cycle length immediately before return to normal sinus rhythm in both models. A dose-response trial was performed in the vagal AF group as well as in a second group of three dogs that underwent chronic fibrillatory pacing. The efficacy of tedisamil was dose dependent, with limited efficacy at 0.1 and 0.3 mg/kg intravenously in both models. Tedisamil was able to prevent reinduction of sustained AF 30 minutes after administration of 1 mg/kg in the chronic pacing model in all dogs. Side effects included minor hypersalivation in most dogs receiving the 1 mg/kg dose. No ventricular ectopy or arrhythmias were observed. CONCLUSION: Tedisamil is effective for conversion of sustained AF to normal sinus rhythm in two different models of AF.

Animals↗
PubMed2005

Pharmacologic control of ventricular rate: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery.

While there is a deficiency in the number of randomized control studies dealing with the pharmacologic control of the ventricular response to atrial fibrillation (AF) or atrial flutter (AFL) after cardiac surgery, evidence-based recommendations are presented from those studies that are available. Because of the hyperadrenergic state after surgery, beta-blockers are recommended as the first line of therapy for patients with AF or AFL who do not require urgent cardioversion. Calcium channel blockers are recommended as second-line therapeutic agents. Digoxin has little efficacy because of the heightened adrenergic tone that is present postoperatively. Agents that are proarrhythmic, such as dofetilide, or agents that are contraindicated in patients with coronary artery disease, such as flecainide and propafenone, are not recommended.

Adrenergic beta-Antagonists↗
PubMed2005

[Analysis of the frequency of cardiac arrhythmias and conduction disturbances from a health-care perspective].

INTRODUCTION AND OBJECTIVES: Over the last few years, our understanding of the mechanisms underlying cardiac arrhythmias has increased substantially. However, few data on their prevalence exist. Our objectives were to analyze the prevalence of cardiac arrhythmias and conduction disturbances in cardiology clinic outpatients and to determine the number of patients with a class-I or -IIa recommendation for electrophysiological studies (EPS). PATIENTS AND METHOD: We investigated cardiac arrhythmias and conduction disturbances in 2045 patients and determined their prevalence in those seen for the first time. Specific conditions investigated included supraventricular and ventricular arrhythmias, ischemic disease with an ejection fraction (EF) <30%, second-degree or higher atrioventricular (AV) block, intraventricular block, and sick sinus syndrome. RESULTS: In total, 798 (39%) of all patients and 153 of the 704 (22%) seen for the first time presented with 1 or more of the specified conditions. Their distribution in all patients was: atrial fibrillation, 524 (26%); atrial flutter, 34 (2%); narrow-QRS tachycardia, 58 (3%); ventricular arrhythmias or EF<30% due to ischemic disease or both, 46 (2%); AV block or sinus dysfunction, 68 (3%); intraventricular block, 157 (8%); and other conditions, 4 (0.2%). Some 7% (143/2045) of all patients and 3.5% (25/704) of those seen for the first time had an indication for EPS. CONCLUSIONS: a) Almost 40% of all patients seen in a cardiology outpatient clinic and 1 in 4 of those seen for the first time presented with a cardiac arrhythmia or conduction disturbance; and b) more than 3% of patients seen for the first time had an indication for EPS.

Adolescent↗
PubMedDate not supplied

Taking the mystery out of rhythm interpretation: atrial electrograms.

OBJECTIVE: To verify cardiac rhythms in which diagnosis from conventional surface recordings was unclear. DESIGN: Approximately five electrograms were recorded each week from randomly selected patients who had undergone cardiac surgery in a two-year period from 1989 to 1991. SETTING: A 1000 bed acute care medical facility that provides care to more than 1300 patients per year after open heart surgery. PATIENTS: Adult patients in the surgical intensive care unit or stepdown units who were recovering from coronary artery bypass grafting, valve replacement or repair, aneurysm resection, and/or atrial and ventricular septal defect repairs. RESULTS: The atrial electrogram was used to diagnose various dysrhythmias. The most frequent application was the verification of atrial flutter, atrial fibrillation, and junctional rhythm. Another use was to differentiate between ventricular tachycardia and supraventricular tachycardia with aberrant conduction. CONCLUSION: Critical care clinicians caring for patients who have undergone cardiac surgery must be proficient at rapid, accurate rhythm interpretation to give appropriate treatment. The use of atrial electrograms can be extremely helpful in rhythm interpretation and clarification for this population of patients.

Arrhythmias, Cardiac↗
PubMed1997

Intravenous Propafenone for Conversion of Atrial Fibrillation or Flutter to Sinus Rhythm: A Randomized, Placebo-controlled, Crossover Study.

BACKGROUND: Propafenone has been claimed to be effective in converting atrial fibrillation and flutter to sinus rhythm; however, controlled clinical trials have reported variable results, and data about the safety of propafenone in the setting of heart failure are lacking. The aim of the present study was to evaluate the efficacy and safety of intravenous propafenone in converting atrial fibrillation and flutter to sinus rhythm. METHODS: Sixty patients with acute (<72 h) or chronic atrial fibrillation or flutter were included in a randomized, placebo-controlled, conditional cross-over study. Twenty eight patients, of whom 12 were in New York Heart Association class III and IV, had heart failure. Patients received intravenous propafenone (2 mg/kg in 10 minutes) and placebo subsequently at 1 hour intervals if sinus rhythm was not achieved. The patients' rhythms were continuously monitored for 1 hour and a 12-lead electrocardiogram, a 1-minute continuous rhythm strip and vital signs were recorded at baseline and at 15, 30, 45, and 60 minutes after the administration of each drug. RESULTS: Twenty of teh 59 patients (34%) treated with propafenone converted to sinus rhythm, while only 4 of the 50 patients (8%) treated with placebo converted (P <.001). Propafenone was more effective in patients with acute (<72 h) atrial fibrillation (64.5%). The conversion rate with propafenone was not significantly different from placebo in patients with atrial flutter and chronic atrial fibrillation (>72 h). Propafenone significantly decreased (P <.005 vs placebo) mean ventricular rate in nonresponders with a baseline heart rate of more than 100 beats/min. No clinically significant adverse effect occurred. CONCLUSIONS: We conclude that intravenous propafenone treatment is effective for converting acute atrial fibrillation; however, it seems unlikely to be beneficial in atrial flutter and chronic atrial fibrillation. Propafenone decreases ventricular rate in nonresponders, and a single dose of propafenone is relatively safe even in moderate-to-severe heart failure.

Journal Article↗
PubMed1986

[Effects of diltiazem in supraventricular paroxysmal tachyarrhythmias].

Diltiazem (0.3 mg/kg body weight intravenous in 2 minutes) was administered to 40 patients (24 males, 16 females, mean age 51.55 years) with paroxysmal supraventricular tachyarrhythmias: 7 patients with atrial fibrillation, 6 patients with atrial flutter, 25 patients with paroxysmal supraventricular tachycardia, 2 patients with uncommon atrioventricular reciprocating tachycardia. In patients with atrial fibrillation intravenous diltiazem produced a significant decrease of ventricular response (from 160 +/- 11 to 113.57 +/- 10.34--p less than 0.01). In patients with atrial flutter intravenous diltiazem produced variable effects: an increase in atrio-ventricular block (from 2:1 to 3:1 atrio-ventricular conduction (2 patients); conversion to sinus rhythm (1 patient); change to atrial fibrillation (1 patient); no appreciable change of the basic rhythm (2 patients). In paroxysmal supraventricular tachycardia patients conversion to sinus rhythm occurred in 20/22 patients (91%) treated with intravenous diltiazem (mean conversion time 4.69 minutes). In the 2 patients with uncommon atrioventricular nodal reciprocating tachycardia diltiazem increased P'-R and R-P' intervals without appreciable change of the basic rhythm. No serious side effects from drug administration were noted. Intravenous diltiazem appears to be as a highly effective medication in conversion or control of paroxysmal supraventricular tachyarrhythmias.

Adolescent↗
PubMed1986

Cardiac abnormalities in patients with diffuse malignant pleural mesothelioma.

Many patients with diffuse malignant pleural mesothelioma have dyspnea or chest pain. Cardiac symptomatology is frequently difficult to differentiate from symptoms of pleuropulmonary disease. To better define the clinical characteristics of cardiac involvement in patients with mesothelioma, the electrocardiographic (EKG) and echocardiographic findings in 64 patients with biopsy-proven malignant pleural mesothelioma were reviewed. A total of 19/64 (30%) patients had autopsy studies available for review. The EKG was abnormal in 55 patients (89%). Over half (60%) had an arrhythmia, including sinus tachycardia (42%), premature atrial and ventricular contractions (13%), atrial fibrillation (3%), and atrial flutter (1%). Over one third (37%) had a conduction abnormality, including bundle branch block (13%), hemiblock (8.5%), and incomplete right bundle branch block (13%). Echocardiography revealed a total of 13 patients with pericardial effusions, two with pericardial thickening, and one with an anterior sonolucent space. Of 19 autopsies, cardiac invasion was found in 14 (74%), with more than half to the pericardium and more than one quarter to the myocardium. It is concluded that: clinical cardiac abnormalities occur in the great majority of patients with malignant pleural mesothelioma, pathologic cardiac invasion occurs in the great majority of patients with pleural mesothelioma, and the EKG and echocardiogram are helpful in differentiating cardiac involvement from progressive pulmonary disease in patients with pleural mesothelioma.

Adult↗
PubMed2005

Is it safe to perform cardiac catheterizations on adults with congenital heart disease in a pediatric catheterization laboratory?

OBJECTIVE: To determine the complication rate during the catheterization in adults with congenital heart disease (CHD) in a pediatric catheterization laboratory (PCL). BACKGROUND: An increasing number of patients with CHD are surviving into adulthood, with diagnostic and interventional cardiac catheterization being essential for the management of their disease. The complication rate during the catheterization of adults with CHD has not been reported. METHODS: A retrospective chart review was performed on all adult patients (>18 years) with CHD who underwent diagnostic or interventional catheterization in our PCL within the past 8.5 years. RESULTS: A total of 576 procedures were performed on 436 adult patients (median age 26 years). Complex heart disease was present in 387/576 (67%) procedures. An isolated atrial septal defect or patent foramen ovale was present in 115/576 (20%) procedures, and 51/576 (9%) procedures were performed on patients with structurally normal hearts with arrhythmias. Interventional catheterization was performed in 378/576 (66%) procedures. There were complications during 61/576 (10.6%) procedures; 19 were considered major and 42 minor. Major complications were death (1), ventricular fibrillation (1), hypotension requiring inotropes (7), atrial flutter (3), retroperitoneal hematoma, pneumothorax, hemothorax, aortic dissection, renal failure, myocardial ischemia and stent malposition (1 each). The most common minor complications were vascular entry site hematomas and hypotension not requiring inotropes. Procedures performed on patients > or = 45 years of age had a 19% occurrence of complications overall compared with 9% occurrence rate in patients of age < 45 years (P < 0.01). CONCLUSIONS: The complication rate during the catheterization of adults with CHD in a PCL is similar to the complication rate of children with CHD undergoing cardiac catheterization. The older subset of patients are more likely to encounter complications overall. The encountered complications could be handled effectively in the PCL. With screening in place, it is safe to perform cardiac catheterization on most adults with CHD in a PCL.

Adolescent↗
PubMed1988

Short- and long-term prognostic importance of complete bundle-branch block complicating acute myocardial infarction.

Among 1013 consecutive patients with acute myocardial infarction (AMI), 104 (10%) developed complete bundle-branch block (BBB). The clinical characteristics and the short- and long-term prognosis were similar in the 53 patients with right and the 51 patients with left BBB. Compared to the 909 patients without this conduction disturbance, these 104 patients were older (64 +/- 9 vs. 58 +/- 10 years, p less than 0.001), more frequently women (26 vs. 17%, p less than 0.05), had a larger infarct (peak CK 1672 +/- 1124 vs. 1356 +/- 1089 IU/l, p less than 0.001), more frequently anterior (60 vs. 37%, p less than 0.001). They had a higher incidence of Killip class greater than 1 (63 vs. 38%, p less than 0.001), pericarditis (40 vs. 23%, p less than 0.001), atrial fibrillation or flutter (22 vs. 12%, p less than 0.01), ventricular fibrillation (15 vs. 9%, p less than 0.05), and atrioventricular block (23 vs. 11%, p less than 0.001). Both hospital mortality (32 vs 10%, p less than 0.001) and 3-year posthospital mortality (37 vs. 18%, p less than 0.001) were much higher among patients with complete BBB. Transient BBB had the same deleterious prognosis as BBB persistent at discharge (mortality 33 vs. 39%, NS). The prognostic importance of BBB was more prominent during the first 6 months after infarction (mortality between 6 and 36 months: 18% with BBB vs. 11% without BBB, NS).

Bundle-Branch Block↗
PubMed1976

Echocardiographic features of combined hypertrophic and membranous subvalvular aortic stenosis: a case report.

Combined hypertrophic and membranous subvalvular aortic stenosis was detected by echocardiography. The diagnosis was established by the discovery of severe asymmetric septal hypertrophy, a membrane in the left ventricular outflow tract, narrowing of the left ventricular outflow tract, as well as high frequency fluttering and premature systolic closure of the aortic valve leaflets.

Aortic Stenosis, Subvalvular↗
PubMed2005

Hypertrophic cardiomyopathy in a patient with Crohn's disease: a case report.

Cardiac manifestations of Crohn's disease are rare; the most common is pericarditis. In the present report we briefly describe a 56-year-old man with Crohn's disease who presented to the emergency department due to paroxysmal atrial flutter. A transthoracic echocardiographic study revealed asymmetric left ventricular hypertrophy without outflow pressure gradient. Reviewing the literature, hypertrophic cardiomyopathy has not been previously described in patients with Crohn's disease.

Cardiomyopathy, Hypertrophic↗